The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men.

På svenska

Author

  • Moniek M Vedder
  • Esther W de Bekker-Grob
  • Hans Lilja
  • Andrew J Vickers
  • Geert J L H van Leenders
  • Ewout W Steyerberg
  • Monique J Roobol

Summary, in English

Prostate-specific antigen (PSA) testing has limited accuracy for the early detection of prostate cancer (PCa).

Publishing year

2014

Language

English

Pages

1109-1115

Publication/Series

European Urology

Volume

66

Issue

6

Document type

Journal article

Publisher

Elsevier

Topic

  • Urology and Nephrology

Status

Published

Research group

  • Clinical Chemistry, Malmö

ISBN/ISSN/Other

  • ISSN: 1873-7560